Journal
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
Volume 37, Issue 1, Pages 17-22Publisher
SPRINGER FRANCE
DOI: 10.1007/s13318-012-0080-2
Keywords
Malaria drug development; Ketotifen; Blood-stage malaria; Liver-stage malaria
Categories
Ask authors/readers for more resources
Ketotifen is known to exhibit antimalarial activity in mouse and monkey malaria models. However, the low plasma levels and short half life of the drug do not adequately explain its in vivo efficacy. We synthesized most of the known metabolites of ketotifen and evaluated their antimalarial activity and pharmacokinetics in mice. Norketotifen, the de-methylated metabolite of ketotifen, was a more potent antimalarial in vitro as compared to ketotifen, and exhibited equivalent activity in vivo against asexual blood and developing liver-stage parasites. After ketotifen dosing, norketotifen levels were much higher than ketotifen relative to the IC50s of the compounds against Plasmodium falciparum in vitro. The data support the notion that the antimalarial activity of ketotifen in mice is mediated through norketotifen.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available